Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Alnylam Receives Positive CHMP Opinion for Hereditary Amyloidosis Treatment
Alnylam Receives Positive CHMP Opinion for Hereditary Amyloidosis Treatment
Alnylam Receives Positive CHMP Opinion for Hereditary Amyloidosis Treatment
Submitted by
admin
on July 27, 2018 - 10:22am
Source:
CP Wire
News Tags:
Alnylam
Patisiran
EMA
hATTR amyloidosis
Headline:
Alnylam Receives Positive CHMP Opinion for Hereditary Amyloidosis Treatment
snippet:
European Medicines Agency reviewed patisiran under the accelerated assessment procedure
Patisiran is currently under priority review as a Breakthrough Therapy with the US FDA
hATTR amyloidosis affects more than 50,000 people worldwide
Do Not Allow Advertisers to Use My Personal information
